ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Clotting Factor Concentrate Pregnancy: Safe to use when clinically indicated; FVIII naturally rises in pregnancy.

Factor VIII Concentrate

Brand names: Advate, Recombinate, Helixate, Kogenate, Octanate

Adult dose

Dose: Dose (IU) = Body weight (kg) × desired FVIII rise (IU/dL) × 0.5
Route: IV (slow bolus or infusion)
Frequency: Varies by bleeding severity and indication
Max: Calculated per body weight and target level
Formula: IU required = weight (kg) × desired increase (%) × 0.5. Mild bleed: 10–20 IU/kg (target 20–40%); Moderate: 20–30 IU/kg (target 40–60%); Major/surgery: 40–50 IU/kg (target 80–100%). Infuse at max 10 mL/min.

Paediatric dose

Dose: 20 IU/kg
Route: IV
Frequency: As per clinical indication
Max: 50 IU/kg/dose for major bleeds
Same formula applies. Children <6 years may need higher doses/kg and more frequent administration due to increased volume of distribution. Prophylaxis: 25–40 IU/kg every other day or 3 times weekly.

Dose adjustments

Renal

No dose adjustment required.

Hepatic

No dose adjustment; hepatic disease may affect FVIII consumption.

Paediatric weight-based calculator

Same formula applies. Children <6 years may need higher doses/kg and more frequent administration due to increased volume of distribution. Prophylaxis: 25–40 IU/kg every other day or 3 times weekly.

Clinical pearls

  • Recombinant FVIII preferred in UK for previously untreated patients
  • Bethesda inhibitor titre: <5 BU = low titre (treat with high-dose FVIII); >5 BU = high titre (use bypassing agents)
  • Prophylaxis reduces joint bleeds and haemophilic arthropathy
  • Half-life ~8–12 hours — may need twice-daily dosing for major bleeds
  • Emicizumab (Hemlibra) now available as weekly SC prophylaxis — major advance

Contraindications

  • Known inhibitors to FVIII (use bypassing agents such as aPCC or emicizumab)

Side effects

  • Inhibitor development (15–25% of severe haemophilia A patients on first exposure)
  • Hypersensitivity reactions
  • Fever and chills
  • Headache
  • Thrombosis (high doses)

Interactions

  • None clinically significant

Monitoring

  • FVIII levels (pre and post-dose)
  • Inhibitor titres annually
  • Signs of allergic reaction

Reference: BNFc; BNF; UKHCDO Clinical Guidelines 2023. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways